[1] Hocquelet A, Balageas P, Laurent C, et al. Radiofrequency ablation versus surgical resection for hepatocellular carcinoma within the Milan criteria: a study of 281 Western patients. Int J Hyperthemia, 2015,31:749-757. [2] 张俊超,林苏,朱月永,等.射频消融治疗临近特殊部位肝癌的并发症及预防.临床肝胆病杂志,2017,33:969-973. [3] 林炳柱,刘小燕.甲胎蛋白联合异常凝血酶原检测在肝癌早期诊断及疗效评估中的价值分析.河北医科大学学报,2017,38:1193-1196. [4] 李雪,丁艳,王念跃.血清异常凝血酶原对原发性肝癌诊断准确性荟萃分析.临床检验杂志,2017,35: 390-395. [5] Pote N,Cauchy F,Albuquerque M,et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol,2015,62:848-854. [6] Toyoda H,Kumada T,Osaki Y,et al.Novel method to measure serum levels of des-γ-carboxy Prothrombin for hepatocellular carcinoma patients taking warfarin:a preliminary report.Cancer Sci,2012,103:921-925. [7] Shuqun C, Mengchao W, Han C, et al. Combination transca-theter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology,2004,51:1445-1447. [8] 王振巍,连俊彦,郑进方.胸腺肽α1对肝癌围手术期免疫功能的影响.中华普通外科杂志,2006,21:229-230. |